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Cycle (from the Greek kyklos, meaning a ring or circle) implies in English a recurrent sequence of events. Medical imagery abounds with cycles: anovulatory, cardiac, citric acid, endometrial, Krebs, mammary, menstrual, etc. The term cycling, to describe the purposeful alternation of antimicrobials, appeared in the mid-1980s, just about the time of the first substitution trials involving aminoglycosides. 2 Despite the success of those early aminoglycoside cycling programs, very few experiences with cycling were reported in the 1990s. With the global problem of antimicrobial resistance, particularly in hospitals, 34 antibiotic cycling has reemerged as one of several potential strategies to control antimicrobial selection of resistance. 56 This issue of the Journal is accompanied by a supplement entitled Antibiotic Cycling. My editorial is intended to put the concept of antibiotic cycling and the content of the Supplement into perspective.
The last decade of this millennium has witnessed a growing concern for the problem of antimicrobial resistance and its impending threat to human health {Newsweek. March 23,1994 :46-52). In the last 20 years, pathogens initially susceptible to penicillin G developed resistance to a range of antimicrobial agents. Nonpathogenic commensals such as the coagulase-negative staphylococci that cover human skin recruited a plethora of resistance genes to plague hospitalized patients, particularly those with plastic devices and prosthetics. Organisms with unpronounceable names overran the cleanest of intensive care units. Some notoriously stubborn bacteria, like the enterococci-already armed with multiple antimicrobial-resistance mechanisms-became resistant to all available agents. 3 Epidemiologists and clinicians alike wondered if there would ever be an end of the resistance parade. In the short term, would pharmaceutical developers reduce antimicrobial research and development in fear of their products being neutralized even before they had substantial use? What was to be done?
As the 1990s progressed, hospital epidemiologists, infection control coordinators, and hospital pharmacists fought back with new strategies to protect patients from resistant microorganisms, to improve hand washing among healthcare workers, and to maximize appropriate antimicrobial exposure. Pharmaceutical companies adopted molecular technology to identify new antimicrobial targets associated with bacterial adhesion, adaptation, and survival. 7, 8 New journals arose dedicated to microbial drug resistance; for example, Microbial Drug Resistance: Mechanism, Epidemiology, and Disease (http://www.liebertpub.com/pubsl.htm). Politicians spoke out against the worsening threat. The government revved its public health engines, and now, as we turn the corner of the new millennium, it is full speed ahead on all these fronts aimed at controlling resistance. Antibiotic cycling is one of the tools being honed to stem the onslaught of emerging and surging resistance in pathogenic microorganisms. What are the data to support the use of cycling? Should we proceed with its implementation?
The major experiments relevant to cycling were done in the mid 1980s, primarily, although not exclusively, in Department of Veterans' Affairs hospitals. 9 Gerding has now summarized this experience with an eye to the future. 10 These aminoglycoside substitution programs, although industry supported, were well constructed and informative. They exploited the ability of amikacin to withstand modification by most known aminoglycoside modifying enzymes as a rationale for substituting amikacin for gentamicin or tobramycin. At most participating hospitals, particularly the During epidemics caused by pathogens resistant to a narrow spectrum of antimicrobial agents. The agent to be cycled should display a similar spectrum of activity but lack the resistance profile. For surgical prophylaxis when two classes of agents are considered equivalent, but the utility of one or both agents is reduced due to increased resistance. Cycles may need to be sufficiently long (s=l year) to elicit measurable benefit For introduction of a newly marketed antimicrobial agent with anticipated equivalent or superior efficacy to a currently used agent whose spectrum of activity has decreased. For use as an alternate agent in a combination regimen (eg, tuberculosis) when the new agent has been shown in vitro to exhibit synergy or improved additive activity.
Minneapolis Veterans' Affairs Medical Center (VAMC), the strategy worked well: replacing gentamicin and tobramycin with amikacin resulted in reduced gentamicin resistance, and, at the Minneapolis VAMC, recycling gentamicin resulted in a subsequent increase in gentamicin resistance. Amikacin resistance remained near baseline during all cycles. 1112 To their credit, the investigators conducting these programs were able to include the large numbers of compliant patients needed for proper statistical analysis. Moreover, these trials occurred at a time when the available antibiotics and the high incidence of gram-negative bacillary infections justified aminoglycoside therapy. Lastly, the outcome measures were straightforward: more aminoglycoside resistance or less (not studied were other outcomes, including quality-of-life indicators, persistent carriage of resistant clones, and cost).
Today the same studies would dictate a broader outcome analysis to include the rates of gram-negative bacillary resistance to third-generation cephalosporins, of methicillinresistant Staphylococcus aureus, and of vancomycin-resistant enterococci. In future cycling studies, investigators must consider confounding variables, such as the effectiveness of the infection control program and the effect of community antimicrobial use on hospital resistance. 13 The so-called ICARE (Intensive Care Antimicrobial Resistance Epidemiology) studies now underway are addressing several potential confounding variables, in particular the infection control measures in intensive care units. 14 What about the results of antibiotic-cycling studies subsequent to the aminoglycoside substitution programs? As new antimicrobials hit the market in the late 1980s, enthusiasm for cycling waned. The new third-generation cephalosporins, polyfluorinated quinolones, carbapenems, and monobactams were to answer all our antimicrobial needs. Far from it! What in fact happened is that extended resistance in gram-negative bacilli emerged and the problem of resistance in gram-positive cocci escalated, particularly with respect to vancomycin resistance in enterococci and the long-awaited arrival of staphylococcal strains insensitive to vancomycin. 15 As discussed in the Supplement article by Lavin, the prospect of antibiotic cycling has reemerged as a singular strategy to minimize the enormous volume of vancomycin use. 16 Several additional cycling or substitution studies recentiy appeared, suggesting that, within the confines of intensive-or special-care areas, short cycles of antimicrobials could modify resistance patterns. Kollef et al studied an antimicrobial change in ventilator-associated pneumonia following cardiac surgery. 17 An initial 6-month cycle of standard therapy with ceftazidime was compared to a second 6-month period using ciprofloxacin. The second period saw a significant decrease in pneumonia, primarily due to reduced incidence of antibiotic-resistant gram-negative bacilli. No second round of ceftazidime was evaluated.
Landman et al employed a formulary change to limit use of vancomycin and other agents by increasing use of (3-lactam-p-lactamase-inhibitor combinations. 18 The changes resulted in a decrease in the prevalence of methicillin-resistant Staphylococcus aureus and ceftazidimeresistant Klebsiella pneumoniae. There was no attempt to cycle back to the previous formulary. Bradley et al evaluated the cycling of piperacillin-tazobactam after ceftazidime and demonstrated that the ceftazidime cycle showed a significant increase in the rectal carriage of vancomycinresistant enterococci in a hematology-oncology ward whose patients were already heavily colonized (P=.0001). 19 Dominguez et al report in the Supplement a new study of 271 neutropenic patients from a hematology-oncology unit that rotated four antimicrobial combinations and found no difference among regimens with regard to efficacy or resistance. 20 Thus, even though the data are sparse, antibiotic cycling studies employing effective implementation and well-defined outcomes do suggest some efficacy.
A major consideration for evaluating cycling strategies has come from work done by the pharmacokinetics group in Buffalo. They found that bacteriologic and clinical outcomes depend on the level of antibiotic concentration, expressed as area under the curve over the minimal inhibitory concentration (AUIC). Hyatt and others from the Buffalo group report in the Supplement that, for therapy of infections due to common nosocomial bacteria, an AUIC =sl25 was associated with failure. 21 Clearly variables other than simply the choice of antimicrobial affect clinical outcome and possibly the selective pressure for resistance.
So how should we proceed with implementation of new cycling trials and programs? Certain scenarios may provide a rationale for a given hospital to initiate a cycling program (Table) . Once a program for cycling has been selected, certain ideal elements should be included in the program, as outlined in the Supplement by Gerding, 10 including the ability to distinguish community from nosocomial strains, to establish a stable infection control program, and to type organisms with genetic methods. 22 While not all elements of an ideal system are needed for the evaluation-or the success-of cycling efforts, both cycling programs and cycling studies will require sizable funding to control confounding variables and to recruit adequate resources. Nevertheless, the current expertise in hospital molecular epidemiology could serve these studies well. Government and industry should recognize the unique opportunity to cooperate in funding such studies. It is encouraging that the Centers for Disease Control and Prevention recently issued a request for applications to fund at least two new cycling initiatives.
Caution is needed in designing and implementing future antibiotic-cycling studies. Previously published mathematical projections of the effectiveness of cycling reached pessimistic conclusions, albeit for infections that had no lasting colonization of the host. 23 Indeed, McGowan, who has studied the epidemiology of antimicrobial resistance for over 30 years, warns of practical pitfalls. 24 Industry itself remains ambivalent about cycling, for, as Lavin has noted, new antimicrobials may have a relatively short or nonprofitable lifespan. 16 Perhaps the greatest threat to antibiotic cycling involves the acquisition and assembly of resistance genes in nosocomial pathogens. 25 Promiscuous transposons contain recombinational hot spots for insertion of integrons containing gene cassettes. Gene cassettes usually contain a single resistance gene that can insert into an array of other resistance genes already present in the transposon. 26 There is good evidence that these genes, although easily shuffled within transposons, are not easily excised. Moreover, a beneficial effect of reduced antibiotic selective pressure on resistance-gene loss has not been well established. Antibiotic-cycling studies should address the issue of resistance-gene persistence, with attention to careful collection and characterization of pathogens (and perhaps commensals) to determine the rate of resistance-gene persistence in transposons in response to cycling. 25 Antibiotic resistance has spawned a broad medical and social pessimism. Nevertheless, the response to emerging and reemerging microbial challenges by medical science has been impressive and, in my view, merits a new optimism. Take the example of human immunodeficiency virus infection, an infection once impossible to treat effectively, that currently is relenting to multidrug therapy using specifically targeted antiretroviral agents. Basic research inside and outside of industry will continue to discover novel antimicrobial targets justifying development of classes of antimicrobials. Molecular tools allow us to track resistance organisms closely and at times to limit their spread substantially. Finally, gene therapy promises a new horizon for thinking about how to eliminate chronic infectious diseases, some with widespread antimicrobial resistance, such as tuberculosis, Lyme disease, malaria, herpes simplex, and Helicobacter infection. Antibiotic cycling, while not a panacea for altering the complex factors of antimicrobial selective pressure, presents as a reasonable strategy to test. Substantial time and effort will elapse before we will know if cycling is effective and broadly applicable or if we are simply spinning our wheels.
